news
UK first country to secure zero-tariff US pharmaceuticals deal
New trade deal to “ignite economic growth” and help boost…
New trade deal to “ignite economic growth” and help boost the UK’s position as a superpower in life sciences.
List view / Grid view
Richard Torbett
news
UK yet to agree on VPAG scheme following accelerated review
While no other country has an identical scheme, analysis of…
While no other country has an identical scheme, analysis of the 2025 payment rate shows the UK is significantly behind comparable countries.
news
UK Government publishes Life Sciences Sector Plan
While a focus on accelerating access for innovative medicines has…
While a focus on accelerating access for innovative medicines has been welcomed, industry representatives caution that current system infrastructure could hinder the plans proposed by the UK Government.
news
Life sciences a “priority sector” in UK Industrial Strategy
The new UK strategy represents a milestone for enhancing international…
The new UK strategy represents a milestone for enhancing international competitiveness and puts into motion the upcoming Life Sciences Sector Plan.
news
BioNTech pledges major UK investment
BioNTech’s commitment aligns with the UK Government’s Plan for Change,…
BioNTech’s commitment aligns with the UK Government’s Plan for Change, which involves accelerating growth of the pharmaceutical industry.
news
Landmark UK-India trade deal insufficient for life sciences, says industry body
The multi-billion-pound deal provides a boost to the UK’s economy,…
The multi-billion-pound deal provides a boost to the UK’s economy, however it lacks provision to aid the country’s growth ambitions, states the ABPI.
news
Novo Nordisk industry membership reinstated
The company now has ABPI membership after a two-year suspension…
The company now has ABPI membership after a two-year suspension involving concerns relating to its compliance with the industry body’s code of conduct.
news
Restoring regulatory excellence “central” to UK life science competitiveness
The Association of the British Pharmaceutical Industry (ABPI) asserts that…
The Association of the British Pharmaceutical Industry (ABPI) asserts that the recommendations will help generate confidence and predictability in medicine regulation in the UK.
article
Life sciences response to 2024 Autumn Budget
Research and innovation is highlighted in the UK’s Autumn Budget…
Research and innovation is highlighted in the UK’s Autumn Budget as a priority ‘crucial national asset’ to aid long-term economic growth.
news
ABPI embraces proposals for pharma’s growth ahead of UK elections
The UK pharmaceutical industry body has invited proposals on economic…
The UK pharmaceutical industry body has invited proposals on economic investment, support for manufacturing, clinical trials and R&D.
news
Oligonucleotide manufacturing centre to open in Scotland
A key goal of the Centre for Process Innovation’s (CPI)…
A key goal of the Centre for Process Innovation’s (CPI) new Oligonucleotide Manufacturing Innovation Centre of Excellence in Scotland, is to plug the current gap between supply and demand for these innovative medicines.
news
Unified vision essential in UK advanced manufacturing
A new report outlines five critical actions for five of…
A new report outlines five critical actions for five of the UK’s leading manufacturing sectors to ensure sustainable innovation growth is achieved.
news
Pharma pushes for UK medicine scheme revision
If proposed changes to the UK’s Statutory Scheme for branded…
If proposed changes to the UK’s Statutory Scheme for branded medicines is implemented, there will be “a negative impact on new product launches, despite any initial exemption in the first three years,” says Astellas.
news
Life sciences sector to receive £650 million funding
Funding to support the UK's life sciences manufacturing, skills and…
Funding to support the UK's life sciences manufacturing, skills and infrastructure has been announced as part of a £650m growth package.
news
Pharma responds to UK government Statutory Scheme rise
The ABPI and Lilly have responded to the UK government’s…
The ABPI and Lilly have responded to the UK government’s confirmed plans to increase the payment percentage in the Statutory Scheme to control the costs of branded medicines.
